From the perspective of China's healthcare system, SUG-CAP as first-line therapy for advanced G/GEJ adenocarcinoma with PD-L1 CPS ≥5 is not cost-effective compared with chemotherapy alone. This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.